Neurovance Says Interim Data From Phase 2a Pilot Study Of EB-1020 SR Shows Stimulant-Like Efficacy, But With Lower Risk Of Abuse, For Adult ADHD
1/9/2014 10:16:14 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms. The 40 patient trial was led by Dr. Andrew J. Cutler at the Florida Clinical Research Center and is the first evaluation of the safety and efficacy of EB-1020 SR in a patient population.
Help employers find you! Check out all the jobs and post your resume.
comments powered by